Even in COVID-19 treatment, targeting EGFR signaling was considered to be an attractive strategy, as its inhibitors may synergistically potentiate the anti-SARS-CoV-2 activity of IFN-I (Matsuyama et al., 2020). This evidence concerns the gene EGFR and COVID-19.